anaemia of chronic kidney disease
Haematology · 2009–2017
4decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| epoetin lambda Anaemia associated with intrinsic renal disease (chronic renal failure) during correction and maintenance therapy phases. | Jul 2017 | Recommended | none received |
| epoetin lambda treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, assessed by a nephrologist,… | Jul 2010 | Recommended with restriction | no section in document |
| epoetin lambda Treatment of anaemia requiring transfusion (haemoglobin level less than 100 g per L) where intrinsic renal disease, assessed by a nephrologist, is the primary… | Jul 2010 | Recommended with restriction | no section in document |
| methoxy polyethylene glycol-epoetin beta Treatment of anaemia requiring transfusion (haemoglobin <100 g/L) where intrinsic renal disease, as assessed by a nephrologist, is the primary cause, in… | Nov 2009 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.